​
​

Cardio Diagnostics Stock (NASDAQ:CDIO)

RevenueOwnershipFinancialsChart
Cardio Diagnostics by TradingView

Previous Close

$0.84

52W Range

$0.17 - $3.56

50D Avg

$1.05

200D Avg

$1.23

Market Cap

$16.56M

Avg Vol (3M)

$602.64K

Beta

5.25

Div Yield

-

CDIO Company Profile

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

7

IPO Date

Jan 14, 2022

Website

CDIO Performance

CDIO Financial Summary

Dec 23Dec 22Dec 21
Revenue-$950.00$901.00
Operating Income$-7.24M$-4.55M$-620.45K
Net Income-$-4.66M$-620.45K
EBITDA$-7.24M$-4.42M$-604.45K
Basic EPS-$-1.51$-0.53
Diluted EPS-$-1.51$-0.53

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
ZURAZura Bio Limited
ATNF180 Life Sciences Corp.
ZVSAZyVersa Therapeutics, Inc.
CNSPCNS Pharmaceuticals, Inc.
PYXSPyxis Oncology, Inc.
VECTVectivBio Holding AG
ELEVElevation Oncology, Inc.
IMMXImmix Biopharma, Inc.
EFTReFFECTOR Therapeutics, Inc.
PHIOPhio Pharmaceuticals Corp.
CYTOAltamira Therapeutics Ltd.
AVROAVROBIO, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.